Annias Immunotherapeutics, Inc. Report issue

For profit Phase 1
Founded: Chapel Hill NC United States (2015)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2016
NCT02864368
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Annias Immunotherapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Medulloblastoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 5